Michael Doe @go_620609f9cd878
24 February, 07:54
The Alzheimer’s disease market is anticipated to grow at an annualized rate of over 13%, till 2030.

The recent approval of Aduhelm™, an amyloid beta-directed antibody has led to players seeking approval for similar therapies; various interventions are being evaluated for the treatment / management of the inherently complex neurodegenerative disease

Roots Analysis has announced the addition of “Alzheimers Disease Market (2nd Edition), 2021-2031” report to its list of offerings.

Limited treatment options and unmet needs are the key drivers of research activity in this domain. Several industry and non-industry players are presently engaged in developing various types of disease modifying interventions and drug / therapy candidates that offer symptomatic relief. Moreover, multiple venture capital firms and other strategic investors have been supporting the research related initiatives of various start-ups. Driven by a rich development pipeline and the efforts of various stakeholders, the market is anticipated to grow at a significant pace in the coming future.

To order this 150+ page report, which features 90+ figures, please visit
https://www.rootsanalysis....

Key Market Insights

More than 240 drug candidates for the treatment of Alzheimer’s disease and associated symptoms are currently being investigated
Over 90% of the therapies are being evaluated across preclinical and clinical stages, either as monotherapies or in combination with other products. Majority of the drugs (60%) are designed for oral administration.

190,000+ patients have been enrolled in over 2,000 clinical trials, worldwide
Clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of around 40% in the last five years. Of the total number of trials, close to 65% have already been completed, while 25% are active and still recruiting patients.

Close to 20,000 articles focused on Alzheimer’s disease and related symptoms have been published since 2017
Several industry and non-industry players engaged in this domain are undertaking numerous initiatives to identify and develop novel therapies for this neurodegenerative condition. Majority (81%) of the articles published by authors affiliated to deemed universities are focused on studying the disease pathology.

Several partnerships were established in this domain, during the period 2017-2021
Maximum number of partnerships were observed to be inked in 2018, indicating a recent rise in the interest of various players engaged in this domain. Majority of the deals were reported to be research and development agreements, representing over 34% of the total number of instances.

Over USD 4 billion has been invested by both private and public investors, since 2013
Of the total, close to USD 2 billion was raised through venture capital financing, representing over 40% of the overall share. On the other hand, 25 instances of debt financing were also reported, wherein players collectively received more than USD 300 million.

North America and Europe anticipated to capture over 90% of market share by 2030
Growth in this domain is anticipated to be primarily driven by encouraging clinical trial results and the growing demand for various therapeutic modalities. It is worth mentioning that disease modifying treatment market is projected to hold over 57% of the total market share by 2030.

To request a sample copy / brochure of this report, please visit https://www.rootsanalysis....

Key Questions Answered
 Who are the leading industry players involved in the Alzheimer’s disease industry?
 Which geographies are the most active in conducting clinical trials on therapies for Alzheimer’s disease?
 Which are the leading funding organizations providing grants in the Alzheimer’s disease industry?
 Which partnership models are commonly adopted by industry stakeholders in the Alzheimer’s disease industry?
 How is the current and future market opportunity, related to Alzheimer’s disease, likely to be distributed across key market segments?

The financial opportunity within the Alzheimer’s disease market has been analyzed across the following segments:
 Type of Treatment
 Symptomatic Treatment
 Disease Modifying Treatment

 Type of Symptomatic Indications
 Dementia
 Insomnia
 Other Psychological Symptoms

 Key Geographical Regions
 North America
 Europe
 Asia-Pacific and RoW’

The report features inputs from eminent industry stakeholder(s), who were very optimistic concerning the adoption of display library technologies. The report includes detailed transcripts of the discussions held with the following industry experts:
 Kenneth Moch (President and Chief Executive Officer, Cognition Therapeutics)
 Mathias Schmidt (Chief Executive Officer, ArmaGen)
 Ram Bhatt (Chief Executive Officer, Chairman and Founder, ICB International)

The research also includes detailed profiles of the companies (listed below) engaged in developing therapies for Alzheimer’s disease; each profile features an overview of the developer, details related to its financials (if available), product portfolio, recent developments, and an informed future outlook.
 AbbVie
 AC Immune
 Actinogen Medical
 Allergan (now part of AbbVie)
 Biogen
 Eisai
 Eli Lilly and Company
 GlaxoSmithKline
 Grifols
 Neurim Pharmaceuticals
 Novartis
 Novo Nordisk
 Roche
 Takeda Pharmaceutical

For additional details, please visit
https://www.rootsanalysis.... or email salesrootsanalysis.com

You may also be interested in the following titles:
1. Squamous Non-Small Cell Lung Cancer Market, 2021-2031
2. Novel T-Cell Immunotherapies Market, 2021-2030
3. HER2 Targeting Therapies Market, 2021-2030

Contact:
Michael Doe @go_620609f9cd878
24 February, 07:48
The globe claim to provide contract fill / finish services for various types of biopharmaceutical drug / therapy products.

Despite the fact that biopharmaceuticals offer significant profit margins, innovator companies are plagued by high costs of development, complex production protocols and special procedures and equipment for fill / finish operations. Consequently, a number of drug manufacturers have demonstrated a preference for outsourcing fill / finish operations of such products.

To order this 480+ page report, which features 350+ figures and 260+ tables, please visit this - https://www.rootsanalysis....

The USD 4.2 billion (by 2030) financial opportunity within the biologics fill / finish services market has been analyzed across the following segments:
 Types of Primary Packaging Containers
 Ampoules
 Cartridges
 Syringes
 Vials

 Types of Biologics
 Peptides / proteins
 Antibodies
 Vaccines
 Cell therapies
 Gene therapies
 Viral products
 Oligonucleotides
 Others

 Company Size
 Small-sized
 Mid-sized
 Large / very large

 Scale of Operation
 Preclinical
 Clinical
 Commercial

 Key Therapeutic Areas
 Cancer
 Infectious diseases
 Autoimmune diseases
 Cardiovascular diseases
 Other indications

 Key Geographical Regions
 North America (US, Canada)
 Europe (UK, France, Germany, Italy, Spain and rest of the Europe)
 Asia-Pacific (Japan, China, South Korea, India and Australia)

The Biologics Fill / Finish Services Market, 2019-2030.”report features the following companies, which we identified to be key players in this domain:
 Advanced BioScience Laboratories (ABL)
 Albany Molecular Research (AMRI)
 Biocon
 BioPharma Solutions
 BioReliance
 Boehringer Ingelheim BioXcellence
 ChemPartner
 Emergent BioSolutions
 IDT Biologika
 Lonza
 LuinaBio
 Mycenax Biotech
 Patheon
 Recipharm
 Vetter Pharma
 WuXi Biologics

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Competitive Landscape

5. Company Competitiveness Analysis

6. Biologics Fill / Finish Service Providers in North America: Company Profiles

7. Biologics Fill / Finish Service Providers in Europe: Company Profiles

8. Biologics Fill / Finish Service Providers in Asia-Pacific: Company Profiles

9. Partnerships and Collaborations

10. Recent Expansions

11. Capacity Analysis

12. Demand Analysis

13. Biologics Manufacturing and Fill / Finish: Key Performance Indicator Analysis

14. Market Sizing and Opportunity Analysis

15. Future Growth Opportunities

16. Case Study: Robotic Systems in Fill / Finish Operations

17. Case Study: Ready-to-Use Packaging Components in Aseptic Fill / Finish Operations

18. Conclusion

19. Interview Transcripts

20. Appendix 1: Tabulated Data

21. Appendix 2: List of Companies and Organizations

To purchase a copy, please visit https://www.rootsanalysis....

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at inforootsanalysis.com

Contact Details
Ben Johnson
+1 (415) 800 3415
ben.johnsonrootsanalysis.com

Roots Analysis
Web: https://www.rootsanalysis....
LinkedIn: https://in.linkedin.com/co...
Twitter: https://twitter.com/RootsA...
Medium: https://medium.com/RootsA...
Pinterest: https://in.pinterest.com/R...
Quora: https://rootsanalysisinsig...
Michael Doe @go_620609f9cd878
24 February, 07:40
Clinical Trial Planning and Design Services Market by Phase of Trial, Industry Trends and Global Forecasts, 2021-2030.

Roots Analysis has announced the addition of Clinical Trial Planning and Design Services Market report to its list of offerings.

During our research, we were able to identify 46 industry players that are engaged in offering clinical trial planning and design services. The clinical trial planning and design services domain is presently dominated by the presence of large firms (70%), followed by mid-sized companies (18%). most of the players engaged in this domain offer study design / protocol development (96%), followed by those providing sample size and power analysis services (83%). Notable examples of players offering more than four services include (in alphabetical order), Cancer Research And Biostatistics (1997), Peter MacCallum Cancer Centre (1949), Singapore Clinical Research Institute (2008) and University of Arizona College of Medicine (2006).

To request a sample copy / brochure of this report, please visit this – https://www.rootsanalysis....

Over the years, clinical research has undergone an evolutionary change, in terms of cost of research, technology used, and duration of the study. Clinical research involves a thorough literature review that helps to collate information on studies that involve interactions with patients and diagnostic clinical trial data, in order to understand the root cause of a disease and its treatment. It is worth highlighting that clinical research involves two major steps, namely study design and study reporting. Further, study design involves three key steps, theoretical design, data collection design and statistical analysis design. Specifically, experimental or non-experimental data collection, sampling or census data collection, and temporal characteristics of the variables to be examined are all aspects of data collection design. On the other hand, study reporting includes guiding principles to carry out concise, explicit and elaborative research.

 Planning Period: This parameter takes into consideration the time period that is required to draw up the protocol, as well as to define the objectives of the trial. It is worth highlighting that the period for planning a clinical trial can take up to a year.
 Duration of a Trial: It takes into consideration the amount of time required to recruit participants, as well as to monitor their reaction and survival rate.
 Comparability of Patients: It takes into consideration the comparability of enrolled patient population with respect to prognostic factors. It is worth mentioning that prognostic factors define the enrolled patient population, help to formulate the objectives of the trial, and provide better treatment strategies. These factors provide valid estimates of the differences in the given treatment and help to evaluate results across different studies.
 Treatment Allocation Ratio: This step helps to reduce bias, balanced comparison between two treatment groups and quantification of errors. It is worth highlighting that patients can be allocated to two different trials at the same time; however, in such cases, patients are usually allocated randomly in a 60:40 or 2:1 ratio.
 Use of Historical Control Group: Historical control group can be used to estimate model parameters during the research design phase, to modify a study, or to augment or replace a control arm. Most of the clinical trials include a control group of patients who have the same characteristics as the specially treated group; however, these patients are not administered with the drug / therapy treatment.
 Treatment Management: The treatment provided to enrolled patients should be administered equally, regardless of their treatment plan. Further, in each therapy group, patients should have the same criteria of response and toxicity.
 Ethical Considerations: Ethical concerns can arise at any point throughout the trial. It is worth mentioning that conditions under which a patient may be withdrawn from the study should be carefully examined, prior to the trial. Further, an international review board must approve all human-related research projects.

To request a free insight to this report - https://www.rootsanalysis....

Key Questions Answered
 Who are the key players engaged in offering clinical trial planning and design services, across the world?
 What are the regulatory guidelines established in different geographies and their requirements related to clinical trial planning and design?
 What kind of partnership models are most commonly adopted by stakeholders engaged in this industry?
 What are the key value drivers of the merger and acquisition activity observed within this domain?
 How is the current and future market opportunity likely to be distributed across key market segments?
 What are the anticipated future trends related to clinical trial planning and design services?

For additional details, please visit - https://www.rootsanalysis.... Or salesrootsanalysis.com

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at inforootsanalysis.com

Contact Details
Ben Johnson
+1 (415) 800 3415
ben.johnsonrootsanalysis.com

Roots Analysis
Web: https://www.rootsanalysis....
LinkedIn: https://in.linkedin.com/co...
Twitter: https://twitter.com/RootsA...
Michael Doe @go_620609f9cd878
18 February, 07:28
The oligonucleotide synthesis, modification and purification services market is estimated to grow at a CAGR of 18%, till 2030, predicts Roots Analysis
The applications of oligonucleotides are vast, even beyond the life science / pharma sector; however, owing to the complexities associated with the synthesis and processing of these molecules, such operations are usually outsourced to capable CMOs

Roots Analysis is pleased to announce the publication of its recent study, titled, “Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2021-2030.”

To request a sample copy / brochure of this report, please visit this – https://www.rootsanalysis....

The report features a detailed study of the current scenario and future potential of the custom synthesis, modification and purification services market for oligonucleotides, which are intended for research, diagnostic, and therapeutic applications. Further, the study underlines an in-depth analysis, highlighting the capabilities of service providers engaged in this domain. In addition to other elements, the study covers:
 A detailed assessment of the current market landscape of oligonucleotide manufacturers focused on research and diagnostic and therapeutic applications.
 An insightful company competitiveness analysis, highlighting the key oligonucleotide manufacturers focused on research and diagnostic, and therapeutic applications, based on supplier strength and service strength.
 Elaborate profiles of key players engaged in offering custom synthesis, modification and purification of oligonucleotides for research and diagnostic, and therapeutic applications.
 A qualitative analysis highlighting the various factors that need to be considered by players engaged in this domain, while deciding whether to manufacture their respective products in-house or engage the services of a service provider.
 A detailed review of the various oligonucleotide-based manufacturing initiatives undertaken by big pharma players (on the basis of revenues generated by top 5 pharmaceutical companies in 2020).
 An analysis of recent partnerships inked between players engaged in oligonucleotide manufacturing, during the period 2014-2021.
 An analysis of the various expansion initiatives undertaken by service providers engaged in this domain, during the period 2016-2021.
 An in-depth analysis of over 90 oligonucleotide-based therapy developers that are likely to partner with contract service providers engaged in this domain.
 A detailed analysis of more than 440 completed and ongoing clinical research studies of various oligonucleotide-based drugs.
 An estimate of the global, installed capacity for the manufacturing of oligonucleotides, based on information provided by various industry stakeholders in the public domain.
 An informed estimate of the annual commercial demand for oligonucleotide-based drugs (in kilograms).
 An elaborate discussion on how the recent COVID-19 pandemic is likely to impact the oligonucleotide synthesis market, along with information on the key initiatives undertaken by players engaged in this domain to overcome the challenges faced due to the pandemic.
 A discussion on affiliated trends, key drivers and challenges, under an elaborate SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.
 A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing custom synthesis, modification and purification services for oligonucleotides.
 A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
 Application Area
 Research and Diagnostic Applications
 Therapeutic Applications

 Type of Oligonucleotide
 Antisense Oligonucleotides
 miRNA
 shRNA
 siRNA
 Others

 Scale of Operation
 Clinical
 Commercial

 Purpose of Production
 In-house Operations
 Outsourced Operations

 Type of Operation
 API
 FDF

 Size of Manufacturer
 Small
 Mid-sized
 Large

 Key Therapeutic Areas
 Autoimmune Disorders
 Cardiovascular Disorders
 Genetic Disorders
 Infectious Diseases
 Metabolic Disorders
 Neuromuscular Disorders
 Oncological Disorders
 Ophthalmic Disorders
 Other Therapeutic Areas

 Key Geographical Regions
 North America
 Europe
 Asia-Pacific and the Rest of the World

Key companies covered in the report
 Agilent Technologies
 Ajinomoto Bio-Pharma Services
 BioSpring
 CordenPharma
 Integrated DNA Technologies
 Kaneka Eurogentec
 LGC Biosearch Technologies
 Lonza
 Microsynth
 Nitto Denko Avecia
 Sigma Aldrich
 STA Pharmaceutical
 Sumitomo Chemical
 Thermo Fisher Scientific
 TriLink Biotechnologies
For more information please click on the following link:
https://www.rootsanalysis....

Other Recent Offerings
1. Pharmaceutical Contract Manufacturing Market (3rd Edition), 2021-2030
2. Biopharmaceutical Contract Manufacturing Market (4th Edition), 2021-2030
3. Antisense Oligonucleotide Therapeutics Market, 2020-2030
4. RNAi Therapeutics Market (2nd Edition), 2019 - 2030

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at inforootsanalysis.com

Contact Information
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.joh
Michael Doe @go_620609f9cd878
18 February, 07:18
The opportunity within the regulatory T-cell therapies market is projected to grow at an annualized rate of ~45%, till 2035.

Treg based therapies have become a research hotspot in the field of immunotherapy due to their ability to prevent / delay graft rejection and control autoimmune responses generated post adoptive transfer in vivo

Roots Analysis has announced the addition of “Regulatory T-Cell (Tregs) Therapies Market, 2021 – 2035” report to its list of offerings.

The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
 A detailed assessment of the current market landscape of drug developers engaged in the development of regulatory T-cell therapies.
 A detailed analysis of more than 180+ completed, ongoing and planned clinical studies of regulatory T-cell therapies.
 Detailed profiles of developers of regulatory T-cell therapies (shortlisted on the basis of the number of pipeline products).
 An analysis of the partnerships that have been established in this domain, in the recent past.
 A detailed analysis of various investments undertaken by companies in this domain.
 A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
 A detailed overview of the current market landscape of Treg cell therapies, along with information on several relevant parameters, such as type of product (Tregs, interleukin 2, monoclonal antibodies, small molecules and others), phase of development (preclinical / discovery, phase I, phase I/II, phase II, phase II / III and phase III), therapeutic area (autoimmune disorders, oncological disorders, post-transplant infection, neurological disorders, metabolic disorders, dermatological disorders, infectious diseases, and others), target indication (diabetes mellitus, graft vs host diseases, post liver transplant infection, post kidney transplant infection, amyotrophic lateral sclerosis, multiple sclerosis, myelodysplastic syndromes, atopic dermatitis and acute myeloid leukemia), source of T-cells (autologous and allogeneic), route of administration (intravenous, subcutaneous and intramuscular), dose frequency (multiple dose and single dose), target patient segment (children, adults and elderly patients), type of therapy (monotherapy and combination therapy) and type of developer (industry and non-industry). In addition, it presents details of the companies developing Treg cell therapies, highlighting their year of establishment, company size, location of headquarters and most active players (in terms of number of pipeline candidates).

 Type of Product
 Tregs
 Interleukins
 Small molecules

 Target Indication
 Crohn’s Disease
 Bipolar Disorder
 Allergic Rhinoconjunctivitis
 COVID 19
 Diabetes Mellitus
 Systemic Lupus Erythematosus
 Alzheimer’s Disease
 Graft Vs Host Disease

 Key Geographical Regions
 North America
 Europe
 Asia Pacific

Key companies covered in the https://www.rootsanalysis....

 Abata Therapeutics
 Cellenkos
 Coya Therapeutics
 ILTOO Pharma
 NEKTAR
 Roche
 Sonoma Biotherapeutics
 TeraImmune
 TRACT Therapeutics

For more information please click on the following link:
https://www.rootsanalysis.... or email salesrootsanalysis.com

Other Recent Offerings
1. CD47 Targeting Therapeutics Market: Industry Trends and Global Forecasts, 2021-2030
2. Antibody Drug Conjugates Market (6th Edition): Industry Trends and Global Forecasts, 2021-2030
3. Novel T-Cell Immunotherapies Market: Industry Trends and Global Forecasts, 2021-2030
4. TIL-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
5. Peptide Therapeutics Market: Industry Trends and Global Forecasts, 2021-2030
6. CRISPR Based Therapeutics Market: Focus on Cartridges, Syringes and Vials
7. (2nd Edition), 2021-2030

Key Questions Answered

 What are the prevalent R&D trends related to Treg cell therapies?
 Which are the key therapeutic areas currently being targeted by Treg cell therapies?
 What are the key challenges faced by stakeholders engaged in this domain?
 Who are the leading industry and non-industry players engaged in the development of Treg cell therapies?
 What are the key geographies where research focused on Treg cell therapies is being conducted?
 What are the key value drivers that are likely to influence the evolution of this upcoming market?
 How is the current and future market opportunity likely to be distributed across key market segments?

About Roots Analysis

perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at inforootsanalysis.com

Contact Information
Roots Analysis Private Limited
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnsonrootsanalysis.com
Michael Doe @go_620609f9cd878
18 February, 07:13
The Protein design and engineering services market is likely to grow at CAGR of over 14% during the period 2021-2035.
In addition to being a time and cost intensive process, protein engineering market is fraught with several challenges; considering the expertise available with protein design and engineering service providers to design novel molecules, drug developers are actively outsourcing their requirements

Roots Analysis is pleased to announce the publication of its recent study, titled, “Protein Design and Engineering Market, 2021–2035.”

To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis....

The study features an in-depth analysis, highlighting the capabilities of protein design and engineering technology and service providers. Amongst other elements, the report features:
 A detailed assessment of the current market landscape of companies offering protein design and engineering services.
 A competitiveness analysis of various service providers segregated into three peer groups based on their employee count, into three categories, namely small (500 employees).
 Elaborate profiles of prominent players (shortlisted based on a proprietary criterion) that offer various protein design and engineering services, across North America, Europe and Asia Pacific.
 A detailed assessment of the current market landscape of protein design and engineering technology providers
 An insightful 2×2 matrix representation of the competitiveness analysis of various protein design and engineering technologies segregated into two peer groups based on the company size of their respective technology provider, namely small (1-50 employees) and mid-sized companies (51-500 employees).
 Elaborate profiles of key players (shortlisted based on a proprietary criterion) that are engaged in offering technologies for protein design and engineering.
 An analysis of the partnerships that have been inked by stakeholders engaged in this domain, during the period 2017-2021 (till September).
 A detailed analysis of over 130 protein / peptide based therapy developers that are likely to partner with protein design and engineering services and technology providers.
 An in-depth analysis of the various patents that have been filed / granted related to protein design and engineering market, during the period 2019 to 2021 (till September)
 An in-depth analysis of completed, ongoing and planned clinical studies of various protein / peptide based therapies during the period 2016-2021 (till September).
 A case study presenting the key characteristics of novel peptide therapeutics, along with information on their applications and advantages, as well as key challenges associated with their development process.
 A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below):
 Type of Protein Engineering Approach Used
 Rational Designing
 Directed Evolution
 Semi - Rational Designing

 Type of Protein
 Antibodies
 Peptides
 Enzymes
 Vaccines
 Others

 Type of Application
 Therapeutics
 Diagnostics

 Types of End User
 Pharma / Biotech Firms
 CROs
 Research / Academic Institutes

 Key Geographical Regions
 North America
 Europe
 Asia-Pacific
 Latin America
 MENA
 Rest of the World

 Transcripts of interviews held with the following senior level representatives of stakeholder companies
 Roman Badik (Chief Executive Officer, Enantis)
 Haibin Chen (Vice President - R&D, Enzymaster)
 Naveen Kulkarni (Chief Executive Officer, Quantumzyme)

Key companies covered in the report
 ATUM
 Creative BioMart
 Creative Biostructure
 Creative Enzymes
 Absolute Antibody
 EUCODIS Bioscience
 Fusion Antibodies
 Innovagen AB
 Zymvol Biomodeling
 Averin Biotech
 EnzymeWorks
 GeNext Genomics
 Quantumzyme
 Arzeda
 Cyrus Biotechnology
 Enzymaster
 Innovative Targeting Solutions
 Proteus by Seqens

For more information, please click on the following link:
https://www.rootsanalysis....

You may also be interested in the following titles:
1. ADC Cytotoxic Payloads / Warheads Market: Products and Services Market: Industry Trends and Global Forecasts, 2021-2035
2. Site Management Organizations (SMO) Market: Industry Trends and Global Forecasts, 2021-2035
3. Glycosylation Analysis Services Market: Industry Trends and Global Forecasts, 2021-2030
4. Display Library Technologies and Affiliated Services Market: Industry Trends and Global Forecast, 2021-2030
5. Peptide Therapeutics Market: Industry Trends and Global Forecasts, 2021-2030

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at inforootsanalysis.com

Contact Information
Roots Analysis Private Limited
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnsonrootsanalysis.com

Roots Analysis
Web: https://www.rootsanalysis....
LinkedIn: https://in.linkedin.com/co...
Twitter: https://twitter.com/RootsA...
Medium: https://medium.com/RootsA...
Pinterest: https://in.pinterest.com/R...
Quora: https://rootsanalysisinsig...
Michael Doe @go_620609f9cd878
11 February, 10:32
Cell Therapy Consumables Market.
To order this detailed 230+ page report, please visit this link

Key Inclusions
 A detailed overview of the overall market landscape of players engaged in offering cell therapy consumables, along with information on several relevant parameters, such as year of establishment, company size, location of headquarters, number and location of consumable facilities, type of consumable (kits, media and reagents), type of cell therapy (dendritic cell therapy, NK cell therapy, stem cell therapy and T-cell therapy), application area (research use and therapeutic use), scale of operation (preclinical, clinical and commercial) and type of end-user (industry and non-industry).
 An in-depth company competitiveness analysis of cell therapy consumable service providers based on their product portfolio strength (type of consumable, number of unique type of cell therapy, number of consumable facilities and application area), service strength (based on its experience and company size) and number of products offered.
 A detailed brand positioning analysis of prominent industry players (shortlisted on the basis of strength of service portfolio), highlighting the current perceptions regarding their proprietary brands across different consumable classes.
 Elaborate profiles of the key players offering cell therapy consumable products. Each profile features a brief overview of the company, details related to cell therapy consumable focused product portfolio, consumable facilities, recent developments and an informed future outlook.
 An analysis of recent developments within the cell therapy consumable industry, highlighting information on several partnerships and collaborations, mergers and acquisitions, and expansion initiatives that have taken place in this domain, during the period 2016-2021.
 A list of over 310 cell therapy developers that are anticipated to partner with cell therapy consumable providers. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account a company's size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development), manufacturing facilities and availability of other cell therapy capabilities.
 An informed estimate of the annual demand for cell therapy consumables (in terms of volume of media required for total number of cells), based on type of cell therapy and key geographical regions.
 An elaborate discussion on the future opportunities / trends within the cell therapy consumables market that are likely to influence the growth of this domain over the coming years.
 An insightful discussion on how the recent COVID-19 pandemic is likely to impact the consumables market for cell therapies, along with information on the key initiatives undertaken by various service providers in order to overcome the challenges faced due to the pandemic.
The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

 Type of Consumable
 Kits
 Media
 Reagents

 Type of Cell Therapy
 Dendritic Cell Therapy
 NK Cell Therapy
 Stem Cell Therapy
 T-Cell Therapy
 Scale of Operation
 Clinical
 Commercial

 Type of End-User
 Industry
 Non-Industry

 Key Geographical Regions
 North America
 Europe
 Asia-Pacific
 Rest of the World

To request sample pages, please visit this link

Key Questions Answered
 Who are the key players, across the world, engaged in offering consumables for cell therapies?
 Which regions have emerged as key hubs in terms of cell therapy consumable related capabilities?
 Which are the most popular media components used for cell therapy consumables?
 What kind of partnership models are most commonly adopted by stakeholders engaged in this industry?
 How is the recent COVID-19 pandemic likely to impact the consumables market for cell therapies?
 What are the key challenges associated with cell therapy consumables?
 What is the current, global demand (kits, media and reagents) for cell therapy consumables in the manufacturing process?
 How is the current and future market opportunity likely to be distributed across key market segments?
 What are the anticipated future trends related to consumables market for cell therapies?

You may also be interested in the following titles:
1. Biospecimen Contract Research Services Market: Industry Trends and Global Forecasts, 2021-2030
2. Pharmaceutical Contract Manufacturing Market (3rd Edition): Industry Trends and Global Forecasts, 2021-2030
3. Cell Therapy Manufacturing Market (4th Edition): Industry Trends and Global Forecasts, 2021-2030
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnsonrootsanalysis.com
Michael Doe @go_620609f9cd878
11 February, 10:22
The outsourced cell therapy consumables market, predicts Roots Analysis

In order to keep pace with ongoing advances related to materials and regulatory scenarios, and to facilitate the cell therapy manufacturing process, cell therapy consumable providers are steadily evolving

Roots Analysis is pleased to announce the publication of its recent study, titled, “Cell Therapy Consumables Market, 2021 – 2031”.

The report features an extensive study on the consumable providers within the cell therapy industry. The study also includes an elaborate discussion on the future potential of this evolving market. Amongst other elements, the report features:

A detailed review of the overall market landscape of peptide-based therapies.
A detailed overview of the overall market landscape of players engaged in offering cell therapy consumables.
An in-depth company competitiveness analysis of cell therapy consumable service providers.
A detailed brand positioning analysis of prominent industry players highlighting the current perceptions regarding their proprietary brands across different consumable classes.
Elaborate profiles of the key players offering cell therapy consumable products.
An analysis of recent developments within the cell therapy consumable industry.
A list of over 310 cell therapy developers that are anticipated to partner with cell therapy consumable providers.
An informed estimate of the annual demand for cell therapy consumables based on type of cell therapy and key geographical regions.
An elaborate discussion on the future opportunities / trends within the cell therapy consumables market that are likely to influence the growth of this domain over the coming years.
An insightful discussion on how the recent COVID-19 pandemic is likely to impact the consumables market for cell therapies.
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Type of Consumable
Kits
Media
Reagents

Type of Cell Therapy
Dendritic Cell Therapy
NK Cell Therapy
Stem Cell Therapy
T-Cell Therapy

Scale of Operation
Clinical
Commercial

Type of End-User
Industry
Non-Industry

Key Geographical Regions
North America
Europe
Asia-Pacific
Rest of the World

Key companies covered in the report

Miltenyi Biotec
STEMCELL technologies
Bio-Techne
Irvine Scientific
Thermo Fisher Scientific
Sartorius
BD Biosciences
Lonza
CellGenix
Corning

For additional details, please visit

https://www.rootsanalysis.... or email salesrootsanalysis.com

You may also be interested in the following titles:

Biospecimen Contract Research Services Market: Industry Trends and Global Forecasts, 2021-2030
Pharmaceutical Contract Manufacturing Market (3rd Edition): Industry Trends and Global Forecasts, 2021-2030
Cell Therapy Manufacturing Market (4th Edition): Industry Trends and Global Forecasts, 2021-2030
Contact:

Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

Ben.johnsonrootsanalysis.com
Michael Doe @go_620609f9cd878
11 February, 10:13
Cell therapy consumables market is projected to grow at a CAGR of 18% during 2021-2031.
For additional details, please visit

https://www.rootsanalysis.... email salesrootsanalysis.com